Sleep Apnea, Circulation and Metabolism in Acromegaly - Before and After Treatment
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Circulation
研究概览
简要总结
The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment.
详细描述
Acromegaly is a rare disease caused by a growth hormone (GH) producing pituitary adenoma. Surgery is primary treatment, whereas medical treatment with a somatostatin analogue (SA), which suppresses GH secretion and reduces tumour size, is used when surgery is insufficient or unfeasible. Acromegaly is associated with metabolic abnormalities which contributes to an increased morbidity and mortality if left untreated. To which extend these abnormalities reverses after treatment, and if treatment modality influences the outcome, remain elusive. The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Recently diagnosed with acromegaly
- •Age above 18
- •Written consent
排除标准
- •Pregnancy
结局指标
主要结局
Circulation
时间窗: At baseline (time of diagnosis) and at an average of 1 years treatment
Sphygmocor: central arterial pressure and pulse wave velocity
Bone metabolism
时间窗: At baseline (time of diagnosis) and at an average of 1 years treatment
HRpQCT scan
Sleep apnea
时间窗: At baseline (time of diagnosis) and at an average of 1 years treatment
ApneaLinkAir: respiratory effort, puls, oxygen saturation, nasal flow and snoring
次要结局
- Heartfunction(At baseline (time of diagnosis) and at an average of 1 years treatment)
- Substrate metabolism; signaling proteins(At baseline (time of diagnosis) and at an average of 1 years treatment)
- Physical activity(At baseline (time of diagnosis) and at an average of 1 years treatment)
- Body composition(At baseline (time of diagnosis) and at an average of 1 years treatment)
- Substrate metabolism; gene targets(At baseline (time of diagnosis) and at an average of 1 years treatment)
- Energy expenditure(At baseline (time of diagnosis) and at an average of 1 years treatment)